Sanofi (SNYNF) Current Assets (2009 - 2026)
Sanofi's (SNYNF) quarterly Current Assets came in at $35.3 billion in Q1 2026, down 23.73% year-on-year from $46.3 billion in Q1 2025, and down 1.98% quarter-over-quarter from $36.0 billion in Q4 2025.
Sanofi (SNYNF) Current Assets (2009 - 2026) Analysis & Trends
Sanofi has disclosed Current Assets across 18 years of filings, most recently posting $35.3 billion for Q1 2026.
- Current Assets for Q1 2026 came in at $35.3 billion, down 23.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.3 billion (down 23.73% YoY), and the FY2025 annual result was $36.0 billion, down 20.83% from the prior year.
- Current Assets came in at $35.3 billion for Q1 2026 at Sanofi, down from $36.0 billion in the prior quarter.
- In the past five years, Current Assets ranged from a high of $46.3 billion in Q1 2025 to a low of $30.3 billion in Q2 2022.
- The 5-year median for Current Assets is $35.3 billion (2026), against an average of $37.1 billion.
- Across the five-year window, Current Assets surged 37.91% in 2024 and declined 23.73% in 2026, its largest moves.
- Sanofi's Current Assets stood at $34.8 billion in 2022, then retreated by 5.18% to $33.0 billion in 2023, then jumped by 37.91% to $45.5 billion in 2024, then dropped by 20.83% to $36.0 billion in 2025, then declined by 1.98% to $35.3 billion in 2026.
- The last three Current Assets figures came in at $35.3 billion (Q1 2026), $36.0 billion (Q4 2025), and $39.8 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | 23.94 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | 54.84 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 59.17 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 33.53 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | 35.02 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | 31.48 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 18.64 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | 42.82 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | 27.21 Bn |
| 10 | Sanofi | - | - | 9.49 Bn | 35.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.31 Bn |
| Dec 31, 2025 | 36.03 Bn |
| Sep 30, 2025 | 39.80 Bn |
| Jun 30, 2025 | 41.90 Bn |
| Mar 31, 2025 | 46.30 Bn |
| Dec 31, 2024 | 45.51 Bn |
| Jun 30, 2024 | 32.39 Bn |
| Dec 31, 2023 | 33.00 Bn |
| Jun 30, 2023 | 32.64 Bn |
| Dec 31, 2022 | 34.80 Bn |
| Jun 30, 2022 | 30.26 Bn |
| Dec 31, 2021 | 34.96 Bn |
| Jun 30, 2021 | 35.53 Bn |
| Dec 31, 2020 | 1.17 Bn |
| Jun 30, 2020 | 38.32 Bn |
| Dec 31, 2019 | 1.08 Bn |
| Jun 30, 2019 | 28.44 Bn |
| Dec 31, 2018 | 6.42 Bn |
| Jun 30, 2018 | 28.57 Bn |
| Mar 31, 2018 | 34.92 Bn |